Fundraising FoxLongwood Fund — 2021 Investments
6 investments dated 2021 · listed companies and verified rows first · show all
Camp4 Therapeutics develops antisense oligonucleotides targeting regulatory RNAs to increase gene expression and restore healthy protein levels for genetic diseases, with an initial focus on treating SYNGAP1-related developmental and epileptic encephalopathy.
BiotechCambridge, US
Richard Young(Director (Class II))Josh Mandel-Brehm(Chief Executive Officer and Director (Class III))in
BoardMICHAEL HIGGINS(Director)JORGE CONDE(Director)inAMIR NASHAT(Director)in
Board seatShaan C. Gandhi· per SEC Form D · filed Oct 2021
Co-investors5AM VenturesAndreessen HorowitzPolaris Partners
Immunitas discovers and develops therapeutic antibodies for cancer and autoimmune diseases, with its lead program targeting CD161 for solid tumors and hematological malignancies.
BiotechDigital HealthMedical DevicesWaltham, US
Amanda Wagner(CEO)inDan Matloff(Executive Officer)Jiaping Gu(Director)Jeffrey Goldberg(Executive Officer, Director)
BoardLaura Brass(Director)inKai Wucherpfennig(Director)
Board seatChristoph Westphal· per SEC Form D
Co-investorsAgent CapitalDC Investment PartnersLifelinkM VenturesMedical Excellence CapitalNovartis Venture Fund+5 more
Axena Health is a women's health company providing non-invasive, clinically tested treatments for pelvic health conditions.
Digital HealthFemTechMedical DevicesBoston, US
Jim O'Connor(Executive Officer)Eileen Maus(Executive Officer, Director)
BoardTara Butler(Director)Adam Stone(Director)Dan Levangie(Director)
Board seatRich Aldrich· per SEC Form D
Co-investorsAscension VenturesWestern Technology InvestmentOSF Ventures
BiotechPhiladelphia, US
Philip R. Johnson, M.D.(Executive Officer, Director)inDora Mitchell(Executive Officer)Lori Forrest(Executive Officer)Leon Moulder, Jr.(Director)Benjamin Lund(Director)in
BoardTomas Kiselak(Director)
Co-investorsAgent CapitalDC Investment PartnersOUP (Osage University Partners)Pfizer Venture InvestmentsQuan CapitalBain Capital Life Sciences+3 more
Rectify Pharma is a biotechnology company developing therapies, with a pipeline that has included work in liver and metabolic disease areas.
BiotechDeep Tech
Rajesh Devraj(President and Chief Executive Officer)inRobert Hughes(Chief Scientific Officer)inPol Boudes(Chief Medical Officer)
Co-investorsAtlas VentureDC Investment PartnersForbion
Boston-based biotech developing drugs against the 'dark genome'/repeatome for autoimmune disease, cancer and neurodegeneration.
Benjamin Greenbaum(Founder)David Ting(Founder)Rosana Kapeller(Founder)
Co-investorsAndreessen HorowitzARCH Venture PartnersGV (Google Ventures)Luma GroupSanofi VenturesAbingworth+11 more
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.